Altimmune
OrganizationHeard in 3 episodes across 2 shows since Aug 2026
Altimmune is a clinical-stage biopharmaceutical company developing peptide-based therapeutics, including treatments for metabolic and liver diseases.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
| Nov 2026 | 1 |
Email alert
Email me when Altimmune comes up on a podcast
One email a week at most, with the new episodes that mention Altimmune. Free, no account needed, unsubscribe in one click.
What experts have said about Altimmune
2 statements · 1 positive · 1 mixed
Cramer favors speculative Altimmune exposure but warns it could become worthless.
“But a $2 stock, count me in. But remember, stocks can go to zero.”
Open the episode · Mad Money w/ Jim Cramer 8/18/26Listen at 39:15
Cramer supports speculative investment in Altimmune at its $2 price.
“But a $2 stock, count me in.”
Open the episode · Mad Money w/ Jim Cramer 8/18/26Listen at 39:15
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring Altimmune, newest first
- Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026 - Oct 10, 2026
Biotech ETFs frame a week of company-specific movesBreaking BiotechOct 10, 2026 - Aug 18, 2026
Cadence faces the AI disruption test as Cramer weighs market fearsMad Money w/ Jim CramerAug 18, 2026